For Thyroid Awareness Month 2025, we will be looking into the latest research and clinical trials focused on thyroid eye disease (TED) in adults. The following list has been carefully curated by evaluating the ongoing Phase 3 trials for TED, specifically targeting adults in the United States. Please note that the dates provided are approximate […]
Read More
Today, we will be looking into the latest research and clinical trials focused on hypertrophic cardiomyopathy in adults. The following list has been carefully curated by evaluating the ongoing Phase 3 trials for hypertrophic cardiomyopathy, specifically targeting adults in the United States. Please note that the dates provided are approximate and subject to change. This […]
Read More
On October 25, 2022, the US Food and Drug Administration (FDA) granted approval for Johnson & Johnson’s Tecvayli® (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma. This approval is specifically for patients who have previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and […]
Read More
AstraZeneca and Daiichi Sankyo have collaboratively submitted a new Biologics License Application (BLA) for accelerated approval in the United States for datopotamab deruxtecan (Dato-DXd). This application aims to provide treatment for adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including […]
Read More
One year ago, Exelixis commenced their phase 2/3 pivotal trial to assess the efficacy of zanzalintinib in combination with pembrolizumab compared to pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Zanzalintinib, an oral drug developed by Exelixis, targets and inhibits receptor tyrosine kinases […]
Read More
Today, we will be looking into the latest research and clinical trials focused on thalassemia in adults. The following list has been carefully curated by evaluating the ongoing phase 3 trials for thalassemia, specifically targeting adults in the United States. Please note that the dates provided are approximate and subject to change. This compilation primarily […]
Read More
Today, we will be looking into the latest research and clinical trials focused on ulcerative colitis in adults. The following list has been carefully curated by evaluating the ongoing Phase 3 trials for moderately to severe ulcerative colitis, specifically targeting adults in the United States. Please note that the dates provided are approximate and subject […]
Read More
Today, we will be looking into the latest research and clinical trials focused on Crohn’s disease in adults. The following list has been carefully curated by evaluating the ongoing Phase 3 trials for Crohn’s disease, specifically targeting adults in the United States. Please note that the dates provided are approximate and subject to change. This […]
Read More
On September 17, 2024, the US Food and Drug Administration (FDA) granted approval for Novartis’s Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of individuals with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early cancer (EBC) at high risk of recurrence, including those with node-negative […]
Read More
Today, we will be looking into the latest research and clinical trials focused on actinic keratosis in adults. The following list has been carefully curated by evaluating the ongoing phase 3 trials for actinic keratosis, specifically targeting adults in the United States. Please note that the dates provided are approximate and subject to change. This […]
Read More